Board of Directors
Ms. Curran has served as a member of our board since November 2016. Since December 2019, Ms. Curran has served as the Chief Executive Officer of Phathom Pharmaceuticals, a late clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for GI diseases, and has more than 20 years of experience in the biopharmaceutical industry. Previously, she was the President, Global Inflammation and Immunology (I&I) Franchise and member of the Executive Committee at Celgene Corporation. Ms. Curran joined in 2013 as the U.S. Commercial Head of the I&I Franchise and built the capabilities and recruited the teams that executed the successful U.S. launch of OTEZLA®. Before Celgene, she served as Senior Vice President and General Manager, Global Women’s Health at Merck and Co. Prior to Merck, Ms. Curran was a General Manager at Schering-Plough where she successfully launched Remicade in Switzerland and Australia. From March 2014 to March 2017, Ms. Curran served as a director of H. Lundbeck A/S. Ms. Curran received her BS and Graduate Diploma of Marketing degrees from the University of Technology in Sydney.